Drugmaker Pfizer ($PFE) is set to report its Q3 earnings results on November 4 before the market opens. Analysts are ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...

Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the stock price has fallen in recent years. That has given it an appealing ...

With big yields, these turnaround stocks look like they are attractively priced for those who can handle some uncertainty.

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Vertex should earn other important approvals through 2030 that could jolt its stock price. It's developing a treatment called zimislecel for type 1 diabetes (T1D), and the therapy is showing the ...

Pfizer (NYSE: PFE) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare. It has developed many medicines over the years; ...

Pfizer Inc. (NYSE:PFE) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 27, Berenberg Bank ...

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Why would Pfizer cut drug prices? President Donald Trump signed ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...